Literature DB >> 24814713

Age-, and gender-specific incidence of vascular parkinsonism, progressive supranuclear palsy, and parkinsonian-type multiple system atrophy in North East Scotland: the PINE study.

Robert Caslake1, Kate Taylor2, Neil Scott3, Clare Harris3, Joanna Gordon3, Katie Wilde3, Alison Murray4, Carl Counsell3.   

Abstract

INTRODUCTION: There have been few incidence studies of vascular parkinsonism (VP), progressive supranuclear palsy (PSP), and parkinsonian-type multiple system atrophy (MSA-P). We measured the age-, gender- and socioeconomic-specific incidence rates for these conditions in north-east Scotland.
METHODS: Incident non drug-induced parkinsonian patients were identified prospectively over three years by several overlapping methods from a baseline primary care population of 311,357. Parkinsonism was diagnosed if patients had two or more cardinal motor signs. Patients had yearly follow-up to improve diagnostic accuracy. Incidence rates using the diagnosis by established research criteria at latest follow-up were calculated for each condition by age, gender, and socioeconomic status.
RESULTS: Of 377 patients identified at baseline with possible or probable parkinsonism, 363 were confirmed as incident patients after median follow-up of 26 months (mean age 74.8 years, SD 9.8; 61% men). The crude annual incidence was 3.2 per 100,000 (95% confidence interval (CI) 2.2-4.3) for VP, 1.7 per 100,000 (95% CI 1.0-2.4) for PSP, and 1.4 per 100,000 (95% CI 0.8-2.1) for MSA-P. VP and MSA-P were more common in men (age-adjusted male to female ratios 2.58 (95% CI 1.65-3.83) and 8.65 (95% CI 4.73-14.5) respectively). Incidence did not vary with socioeconomic status. DISCUSSION: This is the first community-based, prospective study to report the incidence of vascular parkinsonism and the third to report the incidence of PSP and MSA-P. Further follow-up and comparison with similar studies in different populations will yield valuable prognostic and aetiological information on these conditions.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Incidence; Multiple system atrophy; Parkinsonism; Progressive supranuclear palsy; Vascular parkinsonism

Mesh:

Year:  2014        PMID: 24814713     DOI: 10.1016/j.parkreldis.2014.04.013

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  9 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

2.  Cognitive Impairment and Basal Ganglia Functional Connectivity in Vascular Parkinsonism.

Authors:  V Dunet; J Deverdun; C Charroud; E Le Bars; F Molino; S Menjot de Champfleur; F Maury; M Charif; X Ayrignac; P Labauge; G Castelnovo; F Pinna; A Bonafe; C Geny; N Menjot de Champfleur
Journal:  AJNR Am J Neuroradiol       Date:  2016-07-14       Impact factor: 3.825

3.  Development and validation of prognostic survival models in newly diagnosed Parkinson's disease.

Authors:  Angus D Macleod; Ingvild Dalen; Ole-Bjørn Tysnes; Jan Petter Larsen; Carl E Counsell
Journal:  Mov Disord       Date:  2017-10-04       Impact factor: 10.338

Review 4.  Epidemiology of atypical parkinsonian syndromes.

Authors:  Raymond Y Lo
Journal:  Tzu Chi Med J       Date:  2021-01-19

5.  Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord Clin Pract       Date:  2019-11-21

6.  Etiologic Framework for the Study of Neurodegenerative Disorders as Well as Vascular and Metabolic Comorbidities on the Grounds of Shared Epidemiologic and Biologic Features.

Authors:  Jesús de Pedro-Cuesta; Pablo Martínez-Martín; Alberto Rábano; María Ruiz-Tovar; Enrique Alcalde-Cabero; Miguel Calero
Journal:  Front Aging Neurosci       Date:  2016-06-13       Impact factor: 5.750

7.  Predictors of functional dependency in Parkinson's disease.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord       Date:  2016-10       Impact factor: 10.338

8.  Therapeutic Interventions for Vascular Parkinsonism: A Systematic Review and Meta-analysis.

Authors:  Adán Miguel-Puga; Gabriel Villafuerte; José Salas-Pacheco; Oscar Arias-Carrión
Journal:  Front Neurol       Date:  2017-09-22       Impact factor: 4.003

9.  Glitazone use associated with reduced risk of Parkinson's disease.

Authors:  Brage Brakedal; Irene Flønes; Simone F Reiter; Øivind Torkildsen; Christian Dölle; Jörg Assmus; Kristoffer Haugarvoll; Charalampos Tzoulis
Journal:  Mov Disord       Date:  2017-09-01       Impact factor: 10.338

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.